At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 13, 2026 at 16:05 ET
Sana Biotechnology announced a strategic collaboration with Mayo Clinic to accelerate the development and clinical delivery of SC451, its investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. As part of the partnership, Mayo Clinic is making an equity investment in Sana, with an option for additional investment.
- Sana and Mayo Clinic are collaborating to advance SC451, a stem-cell derived islet cell therapy for type 1 diabetes.
- Collaboration focuses on optimizing clinical protocols, surgical techniques, and post-treatment care to support global scalability.
- Mayo Clinic is making an equity investment in Sana, with an option for additional investment.
- SC451 is designed to provide long-term glucose control without insulin or immunosuppression.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access